GSK's Lost Quarter: $3 Billion DoJ Settlement Far Outstrips Net Profit
This article was originally published in The Pink Sheet Daily
If approved, the settlement would set a new record for the pharmaceutical industry in its dealings with the federal government, but would be covered by the firm's existing reserves.
You may also be interested in...
Share buybacks are controversial in the biopharma industry, but European pharma companies, facing tough operating environments and pressures on near-term financials, are planning to invest in them in 2012 more than in recent years.
GlaxoSmithKline PLC’s toughest negotiations this year have been with the federal government.